SERB Pharmaceuticals, a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company are collaborating to bring an important drug for cancer patients to Latin America. Under the agreement, M8 Pharmaceuticals is licensed to register, market and commercialize SERB’s supportive oncology product Voraxaze® (glucarpidase) in Latin America.

Patients receiving glucarpidase had higher adjusted odds of kidney recovery, shorter time to kidney recovery, and a lower mortality rate. West Conshohocken, PA, 11 December 2023: BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without […]

West Conshohocken, PA, 21 September 2023: BTG Pharmaceuticals, a SERB company, announced today that SERB will present in vivo data for PR022, a polyclonal antibody in development as an antidote for ricin poisoning, on the first day of the upcoming North American Congress of Clinical Toxicology (NACCT) in Montreal. The presentation, titled “In vivo viability of […]